Liftstream is an executive search recruitment company in the life sciences sector
Alexion took everyone by surprise in recent weeks by announcing a very sizable acquisition of Boston-based Synageva for $8.4bn. This was a significant deal which will only serve to strengthen valuations of rare disease biotechnology companies, which continue to be in the M&A cross-hairs of both pharmaceutical and big-biotech companies.
This year has been a tumultuous year for the rare diseases market with a number of significant news stories revolving around M&A rumours, regulatory approvals, IPO’s, investments and partnering agreements. Liftstream takes a look at these events: